Chemotherapy
Management of Clinical Failures in Non-ICU Patients with Chronic Obstructive Pulmonary Disease ExacerbationsHabib M.P.Pulmonary Section, Veterans Affairs Medical Center, and the Respiratory Sciences Center, University of Arizona, Tucson, Ariz., USA
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Published online: September 26, 2001
Issue release date: 2001
Number of Print Pages: 8
Number of Figures: 3
Number of Tables: 3
ISSN: 0009-3157 (Print)
eISSN: 1421-9794 (Online)
For additional information: https://www.karger.com/CHE
Abstract
Clinical failure after initial treatment for exacerbations of chronic obstructive pulmonary disease (COPD) occurs in 10–25% of cases. Once the original diagnosis is confirmed, there is a need to optimise therapy, including introducing bronchodilators and corticosteroids. The use of aggressive antibiotic treatment is recommended for patients with risk factors (elderly, more than four exacerbations per year, underlying cardiopulmonary disease) and more severe disease. Fluoroquinolones are a good choice for those patients who failed initial therapy and who require antimicrobials, including those with simple exacerbations, complicated cases with comorbidity, or those with bronchiectasis. Consideration of less common pathogens, such as Pseudomonas aeruginosa infection, should also be considered. Bacteria usually associated with exacerbations are becoming increasingly resistant, and this needs to be considered when deciding on appropriate antibiotic treatment.
© 2001 S. Karger AG, Basel
Related Articles:
References
- Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA: Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Resp Crit Care Med 2000;161:1608–1613.
- Maguire GP, Newman T, DeLorenzo LJ, Brown RB, Stone D: Comparison of a hand-held nebulizer with a metered dose inhaler-spacer combination in acute obstructive pulmonary disease. Chest 1991;100:1300–1305.
- Emerman CL, Cydulka RK: Effect of different albuterol dosing regimens in the treatment of acute exacerbation of chronic obstructive pulmonary disease. Ann Emergency Med 1997;29:474–478.
- Dewan NA, Rafique S, Kanwar B, Satpathy H, Ryschon K, Tillotson GS, Niederman MS: Acute exacerbation of COPD: Factors associated with poor treatment outcome. Chest 2000;117:662–672.
-
Ball P, Harris JM, Lowson D, Tillotson G, Wilson R: Acute infective exacerbations of chronic bronchitis. Q J Med 1995;88:61–68.
- Niewoehner DE, Collins D, Erbland ML: Relation of FEV(1) to clinical outcomes during exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. Am J Resp Crit Care Med 2000;161:1201–1205.
- Eller J, Ede A, Schaberg T, Niederman MS, Mauch H, Lode H: Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function (see comments). Chest 1998;113:1542–1548.
- Miravitlles M, Espinosa C, Fernandez-Laso E, Martos JA, Maldonado JA, Gallego M: Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 1999;116:40–46.
-
Wilson R: Outcome predictors in bronchitis (review). Chest 1995;108(suppl 2):S53–S57.
- O’Brien C, Guest PJ, Hill SL, Stockley RA: Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax 2000;55:635–642.
- Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, Anderson P, Morgan NA: Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999;340:1941–1947.
Article / Publication Details
Published online: September 26, 2001
Issue release date: 2001
Number of Print Pages: 8
Number of Figures: 3
Number of Tables: 3
ISSN: 0009-3157 (Print)
eISSN: 1421-9794 (Online)
For additional information: https://www.karger.com/CHE
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
PubMed ID
